Turkey Company Roundup: Biosimilar Pact, Keytruda Supply, Takeda Deal
This article was originally published in PharmAsia News
TUBITAK (The Scientific and Technological Research Council of Turkey) will produce biosimilars with Nobel Ilac, MSD provides pembrolizumab free to 25 patients in Turkey, Abdi Ibrahim intensifies its R&D efforts, and Takeda purchases a portfolio of new products.
You may also be interested in...
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.
Amid delays in surgical operations caused by shortages of equipment and medtech companies demanding payment of outstanding hospital debts, a strong devaluation of the Turkish lira has put the local health care system on a crisis footing.